Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180695 | 0.85 | EBP (0.60) | EBPSIGMAR1HRH3MAOBLTA4H | |
| SCHEMBL2181323 | 0.84 | EBP (0.60) | EBPSIGMAR1HRH3MAOBLTA4H | |
| SCHEMBL3118394 | 0.79 | EBP (0.64) | EBPSIGMAR1HRH3ESR1 | |
| SCHEMBL4163770 | 0.78 | MAOB (0.64) | EBPSIGMAR1HRH3MAOBACHE | |
| SCHEMBL8015672 | 0.74 | EBP (0.88) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL8602973 | 0.74 | EBP (0.64) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL8015671 | 0.73 | EBP (0.67) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL7116068 | 0.73 | ESR1 (0.65) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL7213535 | 0.73 | EBP (0.76) | EBPSIGMAR1HRH3MAOBLTA4H | |
| SCHEMBL113833 | 0.73 | EBP (0.73) | EBPSIGMAR1HRH3MAOBLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476300-B2 | Selective estrogen receptor modulator for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476300-B2 | Selective estrogen receptor modulator for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476300-B2 | Selective estrogen receptor modulator for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2342189-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF OSTEOARTHRITIS | ELI LILLY AND COMPANY (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010036497-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ELI LILLY AND COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036497-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ELI LILLY AND COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ESRRA, GPER1, ESR2 | EBP 120/4885SIGMAR1 391/4885HRH3 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.